Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report)'s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.15 and traded as high as $3.61. Puma Biotechnology shares last traded at $3.55, with a volume of 127,438 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

Puma Biotechnology Stock Down 1.1%

The business has a fifty day moving average of $3.34 and a 200 day moving average of $3.16. The company has a market capitalization of $175.69 million, a PE ratio of 4.60 and a beta of 1.29. The company has a current ratio of 1.53, a quick ratio of 1.43 and a debt-to-equity ratio of 0.11.

Insider Buying and Selling

In other Puma Biotechnology news, Director Brian M. Stuglik sold 8,100 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $3.39, for a total value of $27,459.00. Following the sale, the director owned 94,958 shares of the company's stock, valued at $321,907.62. This trade represents a 7.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Allison Dorval sold 11,610 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total value of $39,474.00. Following the completion of the sale, the director directly owned 75,390 shares in the company, valued at $256,326. This represents a 13.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 91,660 shares of company stock worth $311,563 over the last ninety days. Company insiders own 23.30% of the company's stock.

Institutional Investors Weigh In On Puma Biotechnology

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its position in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 6,351 shares in the last quarter. Graham Capital Management L.P. purchased a new position in shares of Puma Biotechnology in the 4th quarter valued at approximately $33,000. ProShare Advisors LLC purchased a new stake in shares of Puma Biotechnology in the fourth quarter valued at approximately $36,000. C2C Wealth Management LLC purchased a new stake in shares of Puma Biotechnology in the fourth quarter valued at approximately $37,000. Finally, Causeway Capital Management LLC purchased a new stake in shares of Puma Biotechnology in the first quarter valued at approximately $42,000. Institutional investors and hedge funds own 61.29% of the company's stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.